Rubicon Research Limited — Q3 FY26 earnings call

Call held 3 Feb 2026

Management summary

Rubicon Research Limited reported a robust Q3 FY26, driven by strong revenue growth across both new launches and existing products. The company saw significant improvements in profitability metrics, with PAT growing 91% year-on-year. Management highlighted the increasing productivity of R&D investments and provided updates on the Pithampur facility, which is expected to be operational by mid-2026. Despite increased outsourcing impacting gross margins, the operating EBITDA margin is projected to remain stable within the 22-23% range, reflecting confidence in the business trajectory.

Highlights

  • Revenue for Q3 FY26 was INR476 crores, marking a 52% year-on-year growth.

  • EBITDA for Q3 FY26 stood at INR112 crores, increasing by 59% year-on-year.

  • Profit After Tax (PAT) for Q3 FY26 reached INR73 crores, a significant 91% year-on-year increase.

  • Earnings Per Share (EPS) for Q3 FY26 was reported at 4.41 rupees.

  • Year-to-date (9 months) revenue was INR1,240 crores, up 34%.

  • Year-to-date operating EBITDA was INR282 crores, growing 47% with a 22.7% margin.

  • R&D expense for Q3 FY26 was INR52 crores, representing 11% of revenue, in line with guidance.

  • Return on Capital Employed (ROCE) was strong at 34% as of December 31, 2025.

Key financials

  1. Revenue ₹476 Cr +52%YoY
  2. EBITDA ₹112 Cr +59%YoY
  3. PAT ₹73 Cr +91%YoY
  4. EPS ₹4.41
  5. R&D Expense (% of Revenue) 11%
  6. ROCE 34%

What they filed

Q1 FY27: revenue up 54.0%, net profit up 134.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue255 245 301 278 336 +32%302 +23%390 +30%428 +54%
EBITDA68 64 61 63 79 +16%62 −3%106 +74%125 +98%
Net profit43 38 40 35 46 +7%37 −3%70 +75%82 +134%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Guidance & targets

Margin

  • Operating EBITDA Margin Margin · next several years · High confidence 22%-23%
    And the R&D spends, again, to be around 10% to 11% of revenue for the next several years.

    — Parag Sancheti, CEO

  • Gross Margin Margin · post Pithampur ramp-up · Medium confidence 67%-68%
    And then, we maintain our, let's say, Pithampur's ramps up and our reliance on the outsourced manufacturing reduces, we are confident of going back to our earlier gross margin range of 67%-68%.

    — Nitin Jajodia, CFO

R&D

  • R&D Spend (% of Revenue) R&D · next several years · High confidence 10%-11%
    And the R&D spends, again, to be around 10% to 11% of revenue for the next several years.

    — Parag Sancheti, CEO

  • R&D Productivity R&D · ongoing · High confidence upward of 5x
    So, first of all, Nikhil, one thing, basically, we are confident that the R&D productivity will be upward of 5x. Okay. So, that is...

    — Nitin Jajodia, CFO

  • Cumulative R&D Spend R&D · FY26, FY27, Q1 FY28 · High confidence above INR500 crores
    Now, if we look at our current R&D spend, so we are expecting confidently to keep R&D spend above INR500 crores, if we look at fiscals '26, 27, and Q1 of '28 taken together.

    — Sagar Oak, Senior Vice President, Corporate Development and Strategy

Capacity

  • Pithampur Facility Operationalization Capacity · CY26 · High confidence mid-2026
    At Pithampur, we are on track to operationalizing, kind of doing all the validations by mid of 2026 calendar year, we should be able to complete that and we expect commercialization in quarter one of CY '27.

    — Parag Sancheti, CEO

  • Pithampur Facility Commercialization Capacity · Q1 CY27 · High confidence Q1 CY27

    — Parag Sancheti, CEO

Risks & concerns

  • Pressure on gross margins due to increased outsourcing to meet higher demand.

    medium

    Increased outsourcing, while necessary to meet demand, is currently pressurizing gross margins, though operating EBITDA margin is expected to remain stable.

    Management acknowledged

  • External variability in product approvals, competition, and supply chain disruptions.

    medium

    The company's outlook factors in uncertainties such as approval delays, competition, and potential disruptions in API supply, which are inherent business risks.

    Management acknowledged

Q&A highlights

3 direct
Outlook on specialty portfolio growth, impact on gross margin, and Pithampur facility's role in aiding gross margins. Direct
So, if you see year on year, our overall revenue growth is about -- we've grown, the overall revenue base has grown. And if you see, the specialty share of gross profit has remained in Q2 and Q3 at 31% to 32%. This is higher than 26.9%, which was there in the full year of FY '25. So, we have a very good pipeline. And we are very confident that the business, the composition of specialty will keep on growing.

Reveals the increasing contribution of higher-margin specialty products and management's confidence in its continued growth, while also addressing the Pithampur facility's future impact on margins.

Asked by Harsh Kundnani

Understanding the increasing R&D to revenue multiplier (from 3.3x to 5.7x) and its sustainability. Direct
So, I think it is the, I would say the quality of the pipeline. If you look back, to where Rubicon was five, six years ago, where the portfolio pipeline was, or the portfolio was predominantly generic, but the pipeline was beginning to shape up with more and more specialty, drug device and then in the last three, four years, even branded products coming in.

Explains the strategic shift in R&D focus towards specialty, drug-device combinations, and branded products as the driver for improved R&D productivity, which is crucial for future revenue growth.

Asked by Nikhil Mathur

Sustainability of market share gains in top products and the directional impact of Pithampur's ramp-up on EBITDA margin. Direct
So, on the market share gain, I think we don't comment on specific top 5, top 10. As I said, it's been pretty broad based and it's across our mature products and new launches. And again, the approach we have to market share building is very, very calibrated. ... And coming on to Pithampur and EBITDA margin, as I said, first, as it gets ramped up in CY'27, I think we are confident of the operating EBITDA margin of 22%-23%.

Clarifies that market share gains are broad-based and strategic, not concentrated, and reiterates confidence in maintaining the operating EBITDA margin range even with Pithampur's ramp-up.

Asked by Narottam

3 min read 7 chapters

Detailed narrative

Robust Q3 FY26 Financial Performance

Rubicon Research Limited delivered a strong Q3 FY26, with revenue from operations reaching INR476 crores, a 52% increase year-on-year. This growth translated into significant profitability improvements, as EBITDA grew 59% year-on-year to INR112 crores, and Profit After Tax (PAT) surged 91% year-on-year to INR73 crores. The company reported an Earnings Per Share (EPS) of 4.41 rupees for the quarter, reflecting broad-based growth across both new launches and existing products, with 98% of revenues derived from US dollars.

Strategic R&D Investments and Increasing Productivity

The company maintained its commitment to R&D, with expenses for Q3 FY26 at INR52 crores, representing 11% of revenue, aligning with its guidance of 10-11% for the next several years. Management highlighted a significant improvement in R&D productivity, with the R&D to incremental revenue multiplier increasing from 3.3x (FY21-FY24) to 5.7x (FY23-FY26). This improvement is attributed to a strategic shift towards specialty, drug-device combinations, and branded products, with confidence in maintaining productivity upward of 5x and an aggregate R&D spend above INR500 crores for FY26-FY28.

Pithampur Facility Expansion and Future Capacity

The acquisition of the Pithampur facility, with handover in June 2025, is a key strategic move to build capacity and capability, including high-potent oncology, hormones, and steroids. The facility is on track for operationalization by mid-2026 calendar year, with commercialization expected in Q1 CY27. This expansion is crucial to meet higher-than-anticipated demand and is expected to provide significant leverage for scaling up business, although increased outsourcing in the near term to meet demand is currently pressuring gross margins.

Stable Operating Margins Amidst Growth

Despite the near-term pressure on gross margins due to increased outsourcing, management reaffirmed its confidence in maintaining the operating EBITDA margin within the 22%-23% range. The specialty share of gross profit has increased to 31-32% in Q2 and Q3 FY26, up from 26.9% in FY25, indicating a favorable product mix. Once the Pithampur facility ramps up and reliance on outsourced manufacturing reduces, the company is confident of returning to its earlier gross margin range of 67%-68%.

Healthy Cash Flow and Capital Efficiency

Rubicon demonstrated healthy cash flow generation, with net cash flow from operating activities for Q3 FY26 at INR35 crores (after tax) and INR81 crores before tax. Year-to-date net cash flow from operations stood at INR140 crores. The company's Return on Capital Employed (ROCE) improved to 34%, reflecting a strong focus on capital efficiency. Net working capital at INR607 crores (132 days) was largely in line with previous periods, with 25-30% of inventory allocated to recent and upcoming launches.

Global Expansion and Strategic Pipeline

The company is actively pursuing global expansion beyond the US, with business development teams working on building presence in markets like Saudi Arabia and Europe. While specific market offers are not yet detailed, the strategy involves leveraging its product basket of innovative products across these geographies. The pipeline includes promising areas like intranasal drug delivery for conditions such as Parkinson's disease and traumatic brain injury, with early studies showing significantly enhanced delivery efficiency.

Board of Directors Update

Rubicon Research Limited announced the appointment of Dr. Pradnya Saravade as an Independent Director to its Board. Concurrently, Mr. Anand Agarwal, a nominee from General Atlantic, stepped down. These changes ensure that the board is now equally comprised of Promoter Directors, General Atlantic nominees, and four Independent Directors, enhancing governance and strategic oversight.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls